Clinical Trials · NCT01729819

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

CompletedPhase 2Desmopressin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Ferring Pharmaceuticals
Enrollment
106
Start date
Jan 2013
Locations
24 sites, United States
Primary endpoint
Change in Mean Number of Nocturnal Voids From Baseline
View Desmopressin compound reference